Results 221 to 230 of about 13,626 (296)

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy   +10 more
wiley   +1 more source

Synergistic antiviral activity against human adenovirus through combination of itraconazole and brincidofovir

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 7, Page 1578-1601, April 2026.
Background and Purpose Human adenovirus (HAdV) causes respiratory or gastrointestinal tract infections depending on the virus subtype. While HAdV infections are generally self‐limiting in immunocompetent people, they can result in significant morbidity and mortality in immunocompromised adults and children.
Mohamed Zamzamy   +16 more
wiley   +1 more source

Galectin-3: Integrator of Signaling via Hexosamine Flux. [PDF]

open access: yesBiomolecules
Mukherjee MM, Biesbrock D, Hanover JA.
europepmc   +1 more source

Extracellular Vesicles as Orchestrators of Osteoimmunomodulation in Peri‐Implantitis: Implications for Bone Regeneration

open access: yesClinical Implant Dentistry and Related Research, Volume 28, Issue 2, April 2026.
ABSTRACT Introduction Peri‐implantitis, characterized by inflammatory bone loss, is a leading cause of dental implant failure. Current regenerative strategies face limitations due to the persistent inflammatory microenvironment. Mesenchymal stem cell‐derived extracellular vesicles (MSC‐EVs) have emerged as promising acellular therapeutics with dual ...
Marco Bonilla   +3 more
wiley   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

open access: yesEuropean Journal of Haematology, Volume 116, Issue 4, Page 357-367, April 2026.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta   +12 more
wiley   +1 more source

Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape. [PDF]

open access: yesNat Nanotechnol
Omo-Lamai S   +38 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy